Xie Xiaoliang: The antibody is expected to become a special drug for the new coronary pneumonia

August 8th, at the New Coronary Therapeutic Antibodies and Vaccines Forum of the Global Health Industry Summit, Xie Xiaoliang, Director of the Center for Biomedical Frontier Innovation at Peking University, Director of the Beijing Future Genetic Diagnostics High-Sophisticated Innovation Center, and China
Foreign
, said that so far, we have no small molecular specific drugs for the new coronavirus, and neutral antibodies are expected to become special effects of the new corona pneumonia.
Xie Xiaoliang said that neutral antibodies have a double-edged effect, neither as a therapeutic drug, but also as a short-term preventive drug.
treatment of neo crown pneumonia is in urgent need of strong drugs, plasma therapy, although effective, but due to the limited source of plasma, can not be widely used. The meso-antibodies are produced by the body's immune system and are a key component of plasma therapy.
acid, we're using alkalis to meal, viruses are coming, cells are using antibodies to meal. Therefore, Xie Xiaoliang's team's goal is to quickly find and prepare high-strength meso-antibodies to be injected as a drug instead of plasma.
xie Xiaoliang said that the new coronary pneumonia special effects drug should meet the following criteria, namely, significantly reduce the proportion of patients with mild to severe illness, significantly reduce lung and other tissue damage, rapid cure of patients with mild illness and thus shorten hospital stay.
Using new single-cell genomics techniques, Xie's team of scientists screened more than 400 of the most highly collected IgG antibody sequences from 8,558 antibody sequences in the plasma of more than 60 patients recovering from neocyctic pneumonia to synthesize antibody proteins, from which they found more than 20 highly active median antibodies. Among them, the antibody number BD368-2 is outstanding and has significant therapeutic effect. Xie Xiaoliang's team screened highly active and antibody
the new coronavirus uses its surface pyridrogen (S protein) as the "key" to the virus to "unlock" and invade human cells, and the binding of the S protein receptor binding region (receptor-binding domain, RBD) to the ACE2 receptor on the cell surface is the first step in its invasive cells.
-frozen electroscope structure shows that well-reactive antibodies bind to the binding domain (RBD) on the new coronavirus S protein, thereby preventing it from invading human cells.
note that the BD368-2 medium antibody found by Xie Xiaoliang's team was able to bind to all three RBDs of the S protein, regardless of whether the structure of the RBD is open or closed. The team also found two meso-antibodies that did not fit completely on the table, paired with each other to suppress immune escape.
Using the hACE2
mouse model of professor Qin Chuan of the Chinese Medical
Institute of Experimental Animals, Xie Xiaoliang's team found that treating mice with BD-368-2 after infection with the new coronavirus reduced viral load by about 2,400 times.
found that the mice were injected with BD368-2 antibodies one day before the infection compared to the control group, and that no viral load was detected in the lung tissue of the mice after 5 days.
if BD368-2 antibodies were given 2 hours after infection, the lung viral load in mice dropped significantly after 5 days, while the weight of the mice remained essentially the same.
recently, Xie Xiaoliang's team has conducted more animal experiments. In the hamster experiment, the researchers found that the antibody was given at the same dose (20 mg/kg) of the medium antibody, which was effective even 48 hours after the transfer window was moved to the inoculation virus. Since hamsters metabolize much faster than humans, corresponding to humans, this indicates that the meso-antibodies remain valid 7 to 10 days after a person becomes infected with the new crown, i.e. when the disease develops into a mesoth.
it is understood that for the drug production and experiments of the medium antibody, due to the reduction in the number of domestic patients, the relevant clinical trials will be conducted in Beijing Danshu Pharmaceutical Co., Ltd. under the coordination of Australia and other countries.
previously, on May 17, Xie Xiaoliang's team's work on neutralizing antibodies that are expected to be a powerful drug for the treatment of neo-coronary pneumonia was published online in cell magazine, entitled "Potent neutralizing antibodies antibodies against SARS-CoV-2 identified by high-channel single-sequencing of cells of convalescent patients' 'B cells".